ArticleBMC gastroenterology2026
Association between pan-immune-inflammation and in-hospital mortality in critically ill patients with acute pancreatitis: a cohort study from the MIMIC-IV database.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Global Immune-Nutrition-Inflammation Index (GINI) in Acute Pancreatitis Severity Assessment: A Comparative Study.Digestive diseases and sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pan-immune-inflammation value (PIV) is a novel, readily available biomarker that integrates neutrophil, monocyte, lymphocyte, and platelet counts. This study aimed to evaluate the association between the PIV and in-hospital mortality in critically ill patients with acute pancreatitis. This retrospective cohort study used information from the Medical Information Mart for Intensive Care-IV (MIMIC-IV version 3.1) database. Of 7510 patients screened, 277 fulfilled the inclusion criteria (mean [± SD] age 57.0 ± 17.7 years; 56.3% male). In-hospital and 90-day mortality were 18.4% and 24.9%, respectively. When analyzed as a continuous variable, each per-doubling (1-unit increase) of PIV corresponded to a 21% increase in the odds of in-hospital death across all models (fully adjusted OR 1.21 [95% CI 1.04–1.40]; P = 0.015);When analyzed as a categorical variable, patients in the highest tertile (T3) exhibited a significantly higher risk for in-hospital mortality compared with those in the lowest tertile (T1) (OR = 3.56 [95% CI 1.40–9.05], P = 0.008); the association with 90-day mortality lost significance after full adjustment. RCS revealed a linear relationship between log2-PIV and in-hospital mortality (P for nonlinearity = 0.868). Subgroup analyses revealed no significant interactions(all P > 0.05).Our findings indicate that an elevated PIV is an independent predictor of in-hospital mortality in critically ill patients with AP and may serve as a simple and reliable biomarker for early risk stratification and therapeutic guidance. Larger prospective multicenter studies are needed to validate these findings and explore interventions targeting PIV to improve outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.